Login / Signup

Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer.

Yoichi ShimizuMasato AndoHiroyuki WatanabeMasahiro Ono
Published in: Annals of nuclear medicine (2024)
has the potential to be a SPECT imaging agent for diagnosing high PSMA-expressing prostate cancer.
Keyphrases
  • prostate cancer
  • pet ct
  • pet imaging
  • radical prostatectomy
  • high resolution
  • cancer therapy
  • quantum dots
  • living cells
  • risk assessment
  • human health
  • fluorescent probe